Reading FEMY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track FEMY free→Reading FEMY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track FEMY free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Peer multiples imply a price about 186% below where it trades (it looks expensive on this basis); the read is rich. If FEMY cuts guidance on the next call, that's a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $3.98. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.98, FEMY's earnings are too small for P/E to mean much; on sales it trades at 144× p/s (51.3× the 3× p/s peer median). At a normal multiple the price implies ~787% near-term growth vs our ~15% forecast. That gap is an optionality premium a financial-multiple model can't price — our $0.45 fair value covers only the as-is business, low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 787% near-term growth, well above our forecast of about 15%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Flags: expensive valuation, a turbulent sector regime (Heating).
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 1.52x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
20 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-1.80 → $-1.40 (+22.2% / 30d). 1 raised, 0 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$300.
How much price usually moves either way.
On a bad day, this stock has moved -$1,179.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,087.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Sufficient cash is crucial for operations. A strong cash position can support future growth.
Confirms:Cash reserves reported above $5 million in Q2 2026.
Disproves:Cash reserves reported below $3 million in Q2 2026.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for FEMY yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Material Modification to Rights of Security Holders. On June 5, 2026, Femasys Inc. (the “Company”) filed a Certificate of Amendment to the Eleventh Amended and Restated Certificate of Incorporation of the Company (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its outstanding common stock. The Amendment became effective at 8:40 a.m. Eastern Time on June 5, 2026 (the “Effective Time”). The Amendment was authorized by the stockh…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
FEMY Femasys Inc | Below typical Show detailsSector percentile: 7 of 100 | expensive | elevated |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 74 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 94 of 100 | fair | elevated |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain cash resources to fund operations into the third quarter of 2026.
Implement a 1-for-20 reverse stock split to modify capital structure.
Focus on reducing operating losses to improve overall financial health.
Why it matters: The reverse stock split aims to adjust the capital structure. Its effect on share price will show if it helps attract investors.
Confirms:Share price increases by more than 20% within three months after the split.
Disproves:Share price declines or stays flat after the reverse stock split.
Why it matters: Better operating income means lower costs. This can make investors more confident.
Confirms:Operating income goes up by over 10% from Q1 2026.
Disproves:Operating income goes down or stays the same from Q1 2026.
Results of Operations and Financial Condition. On May 8, 2026 Femasys Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Secti…
Results of Operations and Financial Condition. On March 31, 2026 Femasys Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Se…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (c) On April 1, 2026, Femasys Inc. (the “Company”) announced the hiring and appointment of John Canning as its Chief Operating Officer, effective March 30, 2026. Mr. Canning, age 52, most recently served as Chief Operating Officer at Terumo Aortic from April 2017 to February 2026, where he led global operations and technology functions. Prior to tha…
Entry into a Material Definitive Agreement. As previously announced, pursuant to the Securities Purchase Agreement dated as of November 3, 2025, by and among Femasys Inc. (the “Company”) and the other lenders party thereto (the “Securities Purchase Agreement”), the Company issued to the lenders party to the Securities Purchase Agreement (the “Lenders”) certain (i) Senior Secured Convertible Notes (each, a "Note"), (ii) Series A-1 Warrants, (iii) Series B-1 Warrants, and (iv) Series C-1 Warran…